Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

Inclusion Criteria: * 1\. A clinical diagnosis of external anogenital/perianal warts with at least 2 warts and no more than 20 warts located in one or more of the following anatomic locations: 1. In both sexes: inguinal, perineal, and perianal areas 2. In men: penis shaft, scrotum, glans penis and foreskin 3. In women: on the vulva * 2\. Subjects has a total wart areas of at least 10 mm2, but not more than 500 mm2 * 3\. Female subjects of childbearing potential must be confirmed not pregnant by a negative urine pregnancy test prior to trial treatment Exclusion Criteria: * 1\. Subject has received any topical and/or destructive treatments for external anogenital warts within 4 weeks (within 12 months for imiquimod and within 12 weeks for sinecatechins) prior to enrolment * 2\. Subject suffer from any of the following conditions: 1. Known human immunodeficiency virus (HIV) infection 2. An outbreak of herpes genitalis in the wart areas within 4 weeks prior to enrolment 3. Has internal (rectal urethral, vaginal/cervical) warts that require or are undergoing treatment 4. Has a dermatological disease (e.g. psoriasis) or skin condition in the wart areas * 3\. Subjects using systemic virostatic compounds or immunosuppressive medication within 30 days prior to enrollment * 4\. Prior quadrivalent HPV vaccination